Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 23, Number 10—October 2017

Research

Antimicrobial Drug Prescription and Neisseria gonorrhoeae Susceptibility, United States, 2005–2013

Robert D. KirkcaldyComments to Author , Monina G. Bartoces, Olusegun O. Soge, Stefan Riedel, Grace Kubin, Carlos Del Rio, John Papp, Edward W. Hook, and Lauri A. Hicks
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (R.D. Kirkcaldy, M.G. Bartoces, J.R. Papp, L.A. Hicks); University of Washington, Seattle, Washington, USA (O.O. Soge); Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA (S. Riedel); Texas Department of State Health Services, Austin, Texas, USA (G. Kubin); Emory University, Atlanta (C. Del Rio); University of Alabama at Birmingham, Birmingham, Alabama, USA (E.W. Hook III)

Main Article

Table 1

Antimicrobial drug resistance and reduced susceptibility in gonococcal isolates by drug, Gonococcal Isolate Surveillance Project, United States, 2005–2013*

Results† Cefixime Ceftriaxone Azithromycin Ciprofloxacin
2005
Geometric mean MIC 0.009 0.006 0.189 0.011
Reduced susceptibility, %
0.1
0.1
0.6
10.1
2006
Geometric mean MIC 0.010 0.005 0.204 0.016
Reduced susceptibility, %
0.1
0.1
0.3
15.4
2007
Geometric mean MIC NT 0.010 0.240 0.027
Reduced susceptibility, %

0.1
0.5
16.0
2008
Geometric mean MIC NT 0.010 0.242 0.024
Reduced susceptibility, %

0.1
0.2
14.7
2009
Geometric mean MIC 0.020 0.010 0.192 0.031
Reduced susceptibility, %
0.9
0.3
0.3
10.8
2010
Geometric mean MIC 0.020 0.010 0.174 0.039
Reduced susceptibility, %
1.6
0.4
0.6
14.2
2011
Geometric mean MIC 0.020 0.010 0.171 0.039
Reduced susceptibility, %
1.6
0.4
0.3
14.4
2012
Geometric mean MIC 0.020 0.010 0.183 0.042
Reduced susceptibility, %
1.0
0.3
0.3
16.1
2013
Geometric mean MIC 0.021 0.010 0.202 0.043
Reduced susceptibility, % 0.5 0.1 0.6 17.1

*Results are for 23 sites that participated in GISP for the entire study period. Cefixime MIC testing range was 0.001–0.5 µg/mL during 2005–2006 and 0.015–0.5 µg/mL during 2009–2013; ceftriaxone MIC testing range was 0.001–2.0 µg/mL during 2005–2006 and 0.008–2.0 µg/mL during 2007–2013; azithromycin MIC testing range was 0.008–16 µg/mL during 2005–2006 and 0.03–16 µg/mL during 2007–2013; ciprofloxacin MIC testing range was 0.001–16 µg/mL during 2005–2006 and 0.008–16 µg/mL during 2007–2013. NT, not tested.
†Reduced susceptibility indicates isolate’s resistance or reduced susceptibility to the indicated drug. Reduced cefixime susceptibility was defined as MIC ≥0.25 µg/ml, reduced ceftriaxone susceptibility MIC ≥0.125 µg/mL, reduced azithromycin susceptibility MIC ≥2 µg/mL, and ciprofloxacin resistance defined as MIC ≥1 µg/mL.

Main Article

TOP